AXON - Axovant Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.13
+0.02 (+0.95%)
As of 11:48AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.11
Open2.12
Bid2.12 x 1100
Ask2.13 x 1000
Day's Range2.07 - 2.13
52 Week Range1.02 - 27.98
Volume76,840
Avg. Volume1,592,375
Market Cap260.033M
Beta-0.33
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.70
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Axovant to Present at Two Upcoming Investor Conferences

    BASEL, Switzerland, Sept. 20, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September ...

  • PR Newswire4 days ago

    Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases

    BASEL, Switzerland and SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Roivant Sciences today announced the launch of Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases. Respivant will be led by Chief Executive Officer Bill Gerhart, Executive Vice President for Clinical and Regulatory Ahmet Tutuncu, MD, PhD, and Executive Vice President for Development and Manufacturing Pravin Soni, PhD.

  • What Spark Therapeutics’ Valuation Trend Indicates
    Market Realist7 days ago

    What Spark Therapeutics’ Valuation Trend Indicates

    Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

  • Investors Still Excited about Axovant
    Market Realist8 days ago

    Investors Still Excited about Axovant

    Axovant Sciences (AXON) is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel therapies in neurology and psychiatry. Its product candidates are targeted at neurological diseases, including Parkinson’s disease, oculopharyngeal muscular dystrophy, Lewy body dementia, and other indications. The former is a potential one-time treatment for Parkinson’s disease, and the latter is a potential one-time treatment for oculopharyngeal muscular dystrophy.

  • Analyzing Axovant Sciences’ Valuation Metrics
    Market Realist8 days ago

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.

  • Audentes Therapeutics’ Promising Product Pipeline
    Market Realist8 days ago

    Audentes Therapeutics’ Promising Product Pipeline

    Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit20 days ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • GlobeNewswire23 days ago

    Axovant to Present at Upcoming Investor Conferences

    BASEL, Switzerland, Aug. 29, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor conferences. Dr Cheruvu will present a ...

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Axovant Sciences and Gevo

    NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Gevo and Axovant Sciences had something in common on Tuesday. Axovant Sciences Ltd. was up 14.43% at the close on Tuesday on about 1.5 million shares traded.

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markitlast month

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Puma Biotechnology: Recent Developments and Recommendations
    Market Realistlast month

    Puma Biotechnology: Recent Developments and Recommendations

    In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.

  • Associated Presslast month

    Axovant: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the London-based company said it had a loss of 48 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.08. A year ago, they were trading at $22.89. _____ ...

  • GlobeNewswirelast month

    Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update

    Pipeline expanded with gene therapy technologies including AXO-Lenti-PD for treatment of Parkinson’ s Disease and AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy Ilise Lombardo, MD, promoted ...

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock

    Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.

  • 3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
    Zacks2 months ago

    3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

    Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.

  • Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
    Zacks2 months ago

    Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

    Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

  • Axovant, Benitec Gain on Licensing Deal for Gene Therapy
    Zacks2 months ago

    Axovant, Benitec Gain on Licensing Deal for Gene Therapy

    Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.

  • Axovant and Benitec Biopharma Up on Gene Therapy Development Deal
    Market Realist2 months ago

    Axovant and Benitec Biopharma Up on Gene Therapy Development Deal

    Axovant and Benitec Biopharma Rise on Gene Therapy Licensing DealAxovant and Benitec Biopharma enter into a licensing deal

  • TheStreet.com2 months ago

    Axovant, Benetic Jump on Agreement to Develop Gene Therapy for MD

    Shares of the biopharmaceutical company rose 5% in early morning trading Monday after it announced it had bought the rights to a new gene therapy treatment designed for a rare form of muscular dystrophy from Benitec Biopharma Ltd. Axovant rose 12 cents -- or 5% -- to $2.68 a share on news of the deal while Benitec skyrocketed $1.52 -- or 67.8% --$3.76. The two companies also entered into a research collaboration to develop five more treatments meant to target neurological disorders.

  • GlobeNewswire2 months ago

    Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma

    Axovant Sciences (AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD), and has also entered into a research collaboration for the development of five additional gene therapy products in neurological disorders. The Silence-and-Replace gene therapy technology is designed to deliver a combination of DNA-directed RNA interference (silence) along with a functional copy of the gene (replace) in a single vector construct.

  • Biotech startup Roivant cuts staff, forms two new subsidiaries
    American City Business Journals3 months ago

    Biotech startup Roivant cuts staff, forms two new subsidiaries

    Roivant Sciences, which raised $1.1 billion in equity last summer from the SoftBank Vision Fund and Founders Fund, has confirmed a round of layoffs. According to a prepared statement, the New York-based company said there has been a reduction in headcount of less than 10 percent of all employees. The announcement comes as the company also outlined that it has created two new business units — Roivant Pharma and Roivant Health.

  • Here's Why Axovant Sciences Fell as Much as 21.3% Today
    Motley Fool3 months ago

    Here's Why Axovant Sciences Fell as Much as 21.3% Today

    The meteoric rise in recent weeks is proving unsustainable.